Recent share performance and what it might mean

Illumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly 30% over the past 3 months.

At a share price of US$162.32, Illumina’s recent 30 day share price return of 13.84% and 90 day return of 30.25% sit alongside a 1 year total shareholder return of 96.37%, although the 3 and 5 year total shareholder returns remain negative.

If strong recent gains in Illumina have you thinking about what else might be moving in related areas of the market, it could be a good time to scan 39 healthcare AI stocks

With the stock now at US$162.32 and trading above the average analyst price target, yet showing an intrinsic discount estimate of about 33%, the key question is whether Illumina is still undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 19.3% Overvalued

Illumina closed at $162.32 compared with a narrative fair value of $136.11, which frames the current rally against more conservative long term expectations.

Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long term earnings visibility.

Increasing adoption of next generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.

Want to see what sits behind that confidence in recurring consumables, clinical mix, and future earnings power? The narrative leans on detailed revenue paths, margin assumptions, and a specific future valuation multiple that many investors would usually associate with larger, mature healthcare platforms.

Result: Fair Value of $136.11 (OVERVALUED)

However, there is still clear execution risk, as tighter research funding and tougher China regulation are both capable of undermining the earnings and margin path behind that fair value.

Another way to look at Illumina’s value

The SWS DCF model points to a fair value of about $242.28 per share, which is well above Illumina’s current $162.32 price and implies the stock screens as undervalued on future cash flows. With one model flagging overvaluation and another signaling upside, investors are left to decide which set of assumptions they find more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If you have read this and are still unsure which side of the debate you are on, treat it as a starting point. Move quickly to the underlying data and weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Illumina might be front of mind today, but your next opportunity could be hiding in a very different corner of the market, so do not miss it.

• Target stability and income by scanning companies that focus on reliable shareholder payouts with the 9 dividend fortresses.
• Hunt for potential mispriced opportunities by checking stocks that appear to offer quality at a discount using the 49 high quality undervalued stocks.
• Focus on resilience first by reviewing companies that screen well on financial strength through the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.